Overview

Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.

Phase:

Phase 2

Details

Lead Sponsor:

Tris Pharma, Inc.

Collaborators:

Massachusetts General Hospital
Massachusetts Institute of Technology

Treatments:

Amphetamine